Campath, clones and the cause of autoimmunity-Reference-Cited by-同舟云学术

Campath, clones and the cause of autoimmunity

Published:2022-05-01 Issue:5 Volume:145 Page:1579-1580
ISSN:0006-8950
Container-title:Brain
language:en
Short-container-title:

Author:

Coles Alasdair¹

Affiliation:

1. Department of Clinical Neurosciences, University of Cambridge , Cambridge, UK

Abstract

This scientific commentary refers to ‘Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity’ by Ruck et al. (https://doi.org/10.1093/brain/awac064).

Publisher

Oxford University Press (OUP)

Subject

Neurology (clinical)

Link

https://academic.oup.com/brain/article-pdf/145/5/1579/43948419/awac162.pdf

Reference9 articles.

1. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial;Cohen;Lancet,2012

2. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort;Cossburn;Neurology,2011

3. Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity;Ruck;Brain,2022

4. Lymphopenia, lymphopenia-induced proliferation, and autoimmunity;Sheu;Int J Mol Sci,2021

5. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H);Jones;J Clin Invest,2009

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Esclerosis múltiple: diagnóstico diferencial y tratamiento;Medicine - Programa de Formación Médica Continuada Acreditado;2023-05